Denali Therapeutics market cap DNLI
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Nov 2, 2026
- $3B
- Highest close in our data
- $10.3B
- Dec 2020
Denali Therapeutics is worth $3B at the close on Nov 2, 2026, at $18.86 a share.
That is up 37% over the last year and down 55% over five years.
Its highest close in our data was $10.3B in Dec 2020.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $3B | $2.4B | $4.1B | +22% |
| 2025 | $2.5B | $1.7B | $3.4B | −17% |
| 2024 | $3B | $2.1B | $4.5B | +0% |
| 2023 | $3B | $2.2B | $4.3B | −21% |
| 2022 | $3.8B | $2.8B | $5.1B | −31% |
| 2021 | $5.4B | $5.2B | $9.6B | −46% |
| 2020 | $10B | $1.6B | $10.3B | +472% |
| 2019 | $1.8B | $1.4B | $2.7B | −7% |
| 2018 | $1.9B | $1.2B | $2.1B | n/a |
Against its peers
Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| DNLIDenali Therapeutics | $3B |
| ADMAAdma Biologics | $2.5B |
| VCELVericel | $2.1B |
| KRYSKrystal Biotech | $8.8B |
| RGENRepligen | $9.8B |
| MGTXMeiraGTx | $895.1M |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.6B |
| NBIXNeurocrine Biosciences | $14.8B |
| EXELExelixis | $17.4B |
| ALNYAlnylam Pharmaceuticals | $21.2B |
| Peer median | $10.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Denali Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.